Status:
COMPLETED
Clinical Trial Assessing the Efficacy of Capsaicin Patch (Qutenza®) in Cancer Patients With Neuropathic Pain
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Collaborating Sponsors:
Institut de Cancérologie de la Loire
Conditions:
Neuropathic Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
In the oncology area, neuropathic pains are relatively frequent and can be induced by surgery, radiotherapy, or chemotherapy. In usual practice, some units are using qutenza in order to reduce neuropa...
Detailed Description
Drugs for neuropathic pains are generally represented by antidepressants, anti-epileptics, opioids, lidocaine patch. However, these drugs can frequently be insufficient, and/or can lead to side effect...
Eligibility Criteria
Inclusion
- Patient with at least 18 years old;
- Patient presenting neuropathic pain secondary to an anti-cancerous treatment;
- Patient presenting a DN4 (Neuropathic Pain in Four Questions) score superior or equal to 4 out of 10
- Patient presenting a skin without lesion at the painful area
- Informed consent form signed;
- Patient affiliated to a social security scheme.
Exclusion
- Hypersensitivity known to capsaicin;
- Instable or uncontrolled hypertension;
- Painful area localised next to eyes;
- Pregnant or breastfeeding woman;
- Protected people.
Key Trial Info
Start Date :
November 9 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 20 2021
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT03317613
Start Date
November 9 2017
End Date
December 20 2021
Last Update
February 8 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Jean Perrin
Clermont-Ferrand, France, 63000
2
Centre Hospitalier Emile Roux
Le Puy-en-Velay, France, 43000
3
Institut de Cancérologie Lucien Neuwirth
Saint-Priest-en-Jarez, France, 42271